Log in

NASDAQ:INVA - Innoviva Stock Price, Forecast & News

$13.36
+0.09 (+0.68 %)
(As of 12/12/2019 06:00 AM ET)
Today's Range
$13.21
Now: $13.36
$13.46
50-Day Range
$10.54
MA: $12.31
$13.48
52-Week Range
$10.03
Now: $13.36
$20.54
Volume442,869 shs
Average Volume640,969 shs
Market Capitalization$1.35 billion
P/E Ratio3.78
Dividend YieldN/A
Beta1.52
Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$261 million
Cash Flow$4.14 per share
Book Value$1.57 per share

Profitability

Net Income$395.05 million

Miscellaneous

Employees6
Market Cap$1.35 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.


Innoviva (NASDAQ:INVA) Frequently Asked Questions

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.37 by $0.01. The biotechnology company had revenue of $65.38 million for the quarter. Innoviva had a return on equity of 168.69% and a net margin of 141.80%. View Innoviva's Earnings History.

When is Innoviva's next earnings date?

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Innoviva.

Has Innoviva been receiving favorable news coverage?

Media stories about INVA stock have been trending negative on Thursday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Innoviva.

Are investors shorting Innoviva?

Innoviva saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 11,200,000 shares, a decline of 6.4% from the October 31st total of 11,960,000 shares. Based on an average trading volume of 573,700 shares, the days-to-cover ratio is currently 19.5 days. Approximately 16.5% of the company's shares are short sold. View Innoviva's Current Options Chain.

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:
  • Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.06%), Man Group plc (1.49%), Chicago Equity Partners LLC (0.46%), Millennium Management LLC (0.42%), Assenagon Asset Management S.A. (0.37%) and SG Americas Securities LLC (0.24%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, State Street Corp, Alberta Investment Management Corp, Chicago Equity Partners LLC, James Investment Research Inc., Dupont Capital Management Corp, Municipal Employees Retirement System of Michigan and State of Tennessee Treasury Department. View Insider Buying and Selling for Innoviva.

Which institutional investors are buying Innoviva stock?

INVA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, Millennium Management LLC, Squarepoint Ops LLC, First Trust Advisors LP, Barclays PLC, SG Americas Securities LLC and Redwood Investment Management LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.36.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.35 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva.

What is Innoviva's official website?

The official website for Innoviva is http://www.inva.com/.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]


MarketBeat Community Rating for Innoviva (NASDAQ INVA)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  356 (Vote Underperform)
Total Votes:  627
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Conference Calls

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel